» Articles » PMID: 4847247

Inhibition of in Vivo Insulin Secretion by Prostaglandin E1

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1974 Aug 1
PMID 4847247
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

To determine the effect of prostaglandin E(1) (PGE(1)) infusion upon in vivo insulin secretion, serum insulin responses after an intravenous glucose pulse (2 g) were measured before and during an intravenous infusion of PGE(1) (10 mug/min) in 11 anesthetized dogs. Circulating insulin decreased significantly during PGE(1) infusion were significantly less than control responses. Three dogs received PGE(1) infusions into the thoracic aorta to preclude pulmonic and hepatic degradation of PGE(1) before its arrival at the pancreatic artery; inhibition of insulin secretion was again seen. Inhibition of insulin secretion could not be related to the degree of arterial hypotension induced by intravenous PGE(1), and despite alpha adrenergic blockade with intravenous phentolamine, PGE(1)-induced inhibition of glucose-stimulated insulin responses persisted. Significant increments in systemically circulating PGE levels during intravenous PGE(1) infusions were documented by radioimmunoassay. These studies demonstrate that systemic PGE(1) infusion inhibits insulin secretion and that this effect could not be shown to be dependent upon alpha adrenergic activity.

Citing Articles

Noncanonical Regulation of cAMP-Dependent Insulin Secretion and Its Implications in Type 2 Diabetes.

Ramanadham S, Turk J, Bhatnagar S Compr Physiol. 2023; 13(3):5023-5049.

PMID: 37358504 PMC: 10809800. DOI: 10.1002/cphy.c220031.


The EP3 Receptor/G Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease.

Schaid M, Wisinski J, Kimple M AAPS J. 2017; 19(5):1276-1283.

PMID: 28584908 PMC: 7934137. DOI: 10.1208/s12248-017-0097-1.


Dietary polyunsaturated fatty acids and their metabolites: Implications for diabetes pathophysiology, prevention, and treatment.

Neuman J, Fenske R, Kimple M Nutr Healthy Aging. 2017; 4(2):127-140.

PMID: 28447067 PMC: 5391679. DOI: 10.3233/NHA-160004.


Enriching Islet Phospholipids With Eicosapentaenoic Acid Reduces Prostaglandin E Signaling and Enhances Diabetic β-Cell Function.

Neuman J, Schaid M, Brill A, Fenske R, Kibbe C, Fontaine D Diabetes. 2017; 66(6):1572-1585.

PMID: 28193789 PMC: 5440023. DOI: 10.2337/db16-1362.


Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling.

Carboneau B, Breyer R, Gannon M J Cell Commun Signal. 2017; 11(2):105-116.

PMID: 28132118 PMC: 5440348. DOI: 10.1007/s12079-017-0377-7.


References
1.
Porte Jr D . A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest. 1967; 46(1):86-94. PMC: 297023. DOI: 10.1172/JCI105514. View

2.
Ferreira S, Vane J . Prostaglandins: their disappearance from and release into the circulation. Nature. 1967; 216(5118):868-73. DOI: 10.1038/216868a0. View

3.
BRESSLER R, Lebovitz H . Tranylcypromine: a potent insulin secretagogue and hypoglycemic agent. Diabetes. 1968; 17(10):617-24. DOI: 10.2337/diab.17.10.617. View

4.
Allison S, Chamberlain M, Hinton P . Intravenous glucose tolerance, insulin, glucose, and free fatty acid levels after myocardial infarction. Br Med J. 1969; 4(5686):776-8. PMC: 1630323. DOI: 10.1136/bmj.4.5686.776. View

5.
Taylor S, Saxton C, Majid P, Dykes J, Ghosh P, Stoker J . Insulin secretion following myocardial infarction with particular respect to the pathogenesis of cardiogenic shock. Lancet. 1969; 2(7635):1373-8. DOI: 10.1016/s0140-6736(69)90928-3. View